4.6 Article

Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease

Journal

AMERICAN JOURNAL OF MEDICINE
Volume 125, Issue 4, Pages 399-410

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2011.10.013

Keywords

Angiotensin-converting enzyme inhibitors; Angiotensin receptor blockers; Chronic kidney disease; Systolic heart failure

Funding

  1. National Institutes of Health (NIH) through National Heart, Lung, and Blood Institute [R01-HL085561, R01-HL085561-S, R01-HL097047]
  2. NIH [5UL1 RR025777, R01-DK46199]
  3. Department of Veterans Affairs

Ask authors/readers for more resources

BACKGROUND: The role of renin-angiotensin inhibition in older patients with systolic heart failure with chronic kidney disease remains unclear. METHODS: Of the 1665 patients (aged >= 65 years) with systolic heart failure (ejection fraction < 45%) and chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)), 1046 received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Propensity scores for the receipt of these drugs, estimated for each of the 1665 patients, were used to assemble a matched cohort of 444 pairs of patients receiving and not receiving these drugs who were balanced on 56 baseline characteristics. RESULTS: During more than 8 years of follow-up, all-cause mortality occurred in 75% and 79% of matched patients with chronic kidney disease receiving and not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, respectively (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.74-0.996; P = .045). There was no significant association with heart failure hospitalization (HR, 0.86; 95% CI, 0.72-1.03; P = .094). Similar mortality reduction (HR, 0.83; 95% CI, 0.70-1.00; P = .046) occurred in a subgroup of matched patients with estimated glomerular filtration rate less than 45 mL/min/1.73 m(2). Among 171 pairs of propensity-matched patients without chronic kidney disease, the use of these drugs was associated with a significant reduction in all-cause mortality (HR, 0.72; 95% CI, 0.55-0.94; P = .015) and heart failure hospitalization (HR, 0.71; 95% CI, 0.52-0.95; P = .023). CONCLUSION: Discharge prescription of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant modest reduction in all-cause mortality in older patients with systolic heart failure with chronic kidney disease, including those with more advanced chronic kidney disease. Published by Elsevier Inc. The American Journal of Medicine (2012) 125, 399-410

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available